Table 2.
VIA, Cytology and HPV results at baseline, 2 months and 6 months of participants enrolled in a RCT of AV2 versus placebo in Kinshasa, DRC.
| Baseline |
2 months |
6 months |
|||||
|---|---|---|---|---|---|---|---|
| Variable | AV2 | Placebo | AV2 | Placebo | AV2 | Placebo | |
| VIA | n = 168 (%) | n = 159 (%) | n = 142 (%) | n = 131 (%) | n = 95 (%) | n = 94 (%) | |
| Positive | 168 (51.4) | 159 (48.6) | 27 (19) | 25 (19.1) | 7 (7.4) | 9 (9.6) | |
| Negative | – | – | 115 (81) | 106 (80.9) | 88 (92.6) | 85 (90.4) | |
| Cytology | n = 168 | n = 159 | n = 142 | n = 131 | n = 95 | n = 94 | |
| NILM | 131 (77.9) | 116 (72.9) | 104 (73.2) | 94 (71.7) | 67 (70.5) | 60 (63.8) | |
| ASCUS | 16 (9.5) | 15 (9.4) | 5 (3.5) | 7 (5.3) | 5 (5.2) | 13 (13.8) | |
| AGC | 0 (0.0) | 1 (0.6) | 2 (1.4) | 0 (0.0) | 0 (0.0) | 2 (2.1) | |
| LSIL | 5 (2.9) | 4 (2.5) | 10 (7.0) | 9 (6.8) | 7 (7.3) | 4 (4.2) | |
| ASCH | 2 (1.1) | 2 (1.2) | 5 (3.5) | 5 (3.8) | 6 (6.3) | 2 (2.1) | |
| HSIL | 9 (5.3) | 10 (6.2) | 7 (4.9) | 8 (6.1) | 7 (7.3) | 9 (9.5) | |
| ADENO | 0 (0.0) | 1 (0.6) | 1 (0.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| SCC | 1 (0.6) | 1 (0.6) | 1 (0.7) | 3 (2.2) | 1 (1.0) | 2 (2.1) | |
| Uknown | 4 (2.3) | 9 (5.6) | 7 (4.9) | 5 (3.8) | 2 (2.1) | 2 (2.1) | |
| HPV result | n = 168 | n = 159 | n = 142 | n = 131 | n = 95 | n = 94 | |
| Positive | 52 (31) | 52 (32.7) | 36 (25.4) | 36 (27.5) | 22 (23.2) | 33 (35.1) | |
| Negative | 116 (69) | 107 (67.3) | 106 (74.6) | 95 (72.5) | 73 (76.8) | 61 (64.9) | |